FR3058159B1 - Variants de polypeptide fc presentant une demi-vie augmentee - Google Patents

Variants de polypeptide fc presentant une demi-vie augmentee Download PDF

Info

Publication number
FR3058159B1
FR3058159B1 FR1660495A FR1660495A FR3058159B1 FR 3058159 B1 FR3058159 B1 FR 3058159B1 FR 1660495 A FR1660495 A FR 1660495A FR 1660495 A FR1660495 A FR 1660495A FR 3058159 B1 FR3058159 B1 FR 3058159B1
Authority
FR
France
Prior art keywords
polypeptide
life
variants
increased half
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1660495A
Other languages
English (en)
Other versions
FR3058159A1 (fr
Inventor
Celine Monnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Priority to FR1660495A priority Critical patent/FR3058159B1/fr
Priority to EP17798138.8A priority patent/EP3532503A1/fr
Priority to US16/345,620 priority patent/US20190292269A1/en
Priority to PCT/EP2017/077689 priority patent/WO2018078138A1/fr
Publication of FR3058159A1 publication Critical patent/FR3058159A1/fr
Application granted granted Critical
Publication of FR3058159B1 publication Critical patent/FR3058159B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un variant d'un polypeptide parent comprenant un fragment Fc, ledit variant présentant une demi-vie améliorée par rapport audit polypeptide parent, et comprenant au moins une mutation du fragment Fc augmentant la liaison du Fc au FcRn; et au moins une mutation du fragment Fc augmentant la sialylation du Fc.
FR1660495A 2016-10-28 2016-10-28 Variants de polypeptide fc presentant une demi-vie augmentee Active FR3058159B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1660495A FR3058159B1 (fr) 2016-10-28 2016-10-28 Variants de polypeptide fc presentant une demi-vie augmentee
EP17798138.8A EP3532503A1 (fr) 2016-10-28 2017-10-27 Variants de polypeptide fc presentant une demi-vie augmentee
US16/345,620 US20190292269A1 (en) 2016-10-28 2017-10-27 Fc polypeptide variants having an increased half-life
PCT/EP2017/077689 WO2018078138A1 (fr) 2016-10-28 2017-10-27 Variants de polypeptide fc presentant une demi-vie augmentee

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1660495A FR3058159B1 (fr) 2016-10-28 2016-10-28 Variants de polypeptide fc presentant une demi-vie augmentee
FR1660495 2016-10-28

Publications (2)

Publication Number Publication Date
FR3058159A1 FR3058159A1 (fr) 2018-05-04
FR3058159B1 true FR3058159B1 (fr) 2022-02-25

Family

ID=57750233

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1660495A Active FR3058159B1 (fr) 2016-10-28 2016-10-28 Variants de polypeptide fc presentant une demi-vie augmentee

Country Status (4)

Country Link
US (1) US20190292269A1 (fr)
EP (1) EP3532503A1 (fr)
FR (1) FR3058159B1 (fr)
WO (1) WO2018078138A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634488B2 (en) 2017-07-10 2023-04-25 International—Drug—Development—Biotech Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
KR20230142831A (ko) 2021-01-13 2023-10-11 비스테라, 인크. 인간화된 보체 5a 수용체 1 항체 및 이의 사용 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601822A1 (de) 1986-01-22 1987-07-23 Peter Stenzel Mit einem druckmedium arbeitende betaetigungsvorrichtung
FR2816319B1 (fr) 2000-11-08 2004-09-03 Millegen Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires
FR3024453B1 (fr) * 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree

Also Published As

Publication number Publication date
EP3532503A1 (fr) 2019-09-04
WO2018078138A1 (fr) 2018-05-03
US20190292269A1 (en) 2019-09-26
FR3058159A1 (fr) 2018-05-04

Similar Documents

Publication Publication Date Title
CY1124213T1 (el) Διαβιβαστες aav που περιεχουν γονιδιο κωδικοποιησης του παραγοντα viii
MA40138A1 (fr) Polypeptide présentant une activité de dégradation de polyester et utilisations de celui-ci
FR3098819B1 (fr) Bande de Roulement
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA40882B1 (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
EP4268852A3 (fr) Virus adéno-associés variants et procédés d'utilisation
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
SG196839A1 (en) Antibodies against fcrn and use thereof
CO2018011151A2 (es) Proceso de producción de raav a base de columnas completamente escalable
EA200701974A1 (ru) Получение каротиноидов в олеагенных дрожжах и грибах
FR3058159B1 (fr) Variants de polypeptide fc presentant une demi-vie augmentee
NO20071419L (no) Polypeptidvarianter med endret effektorfunksjon
MX2020012816A (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
EA200700210A1 (ru) ВАРИАНТЫ ОБЛАСТИ Fc
NZ756224A (en) Polypeptide variants and uses thereof
PE20230381A1 (es) Proteina de union a rgma
MX2019010155A (es) Arnm de cftr optimizado por codón novedoso.
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
EA202190822A1 (ru) Технологии для выполнения действий на основе обнаружения объектов
MX2022008659A (es) Moléculas de anticuerpos específicos contra c5ar1 y usos de estas.
Kariper Çevre eğitiminde su ve su kirliliğinin önemi
FR3001729B1 (fr) Mutants du facteur x
MX2020010092A (es) Variantes de anticuerpo c-terminales.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180504

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

CA Change of address

Effective date: 20221108

PLFP Fee payment

Year of fee payment: 8